Home | Welcome to Contract Pharma   
Last Updated Friday, October 31 2014
Print

Irvine Pharmaceutical Services To Expand



Published March 6, 2013
Irvine Pharmaceutical Services has plans to significantly increase capacity over the course of this fiscal year that will double capacity for filling (both lyophilized and liquid), formulation, and biopharmaceutical development by 2Q14.   
 
As part of this initiative, the company incorporated its Avrio parenteral manufacturing facility into the Irvine brand in January. Irvine has since increased technical staff across most departments and plans to add an additional 40 employees during the next 12 months.
 
Dr. Assad J. Kazeminy, Irvine’s chief executive officer and founder, described the plans as “a three-prong initiative for aggressive yet stable growth, with more highly trained technical personnel, state-of-the-art instrumentation and increased capacity for formulation, biopharmaceuticals and raw material testing.”
 
“We have been building to this trajectory for the past five years,” Dr. Kazeminy said. “We are ‘just in time’ to meet the quickly expanding needs of the biopharmaceutical industry as it adjusts to an improving economy, mounting regulatory restrictions and faster-to-market demands.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On